

Vishal C Patel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/773483/publications.pdf>

Version: 2024-02-01

58
papers

2,355
citations

304743

22
h-index

243625

44
g-index

59
all docs

59
docs citations

59
times ranked

3288
citing authors

#	ARTICLE	IF	CITATIONS
1	High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial. <i>Journal of Hepatology</i> , 2016, 64, 69-78.	3.7	466
2	Patients With Acute-on-Chronic Liver Failure Have Increased Numbers of Regulatory Immune Cells Expressing the Receptor Tyrosine Kinase MERTK. <i>Gastroenterology</i> , 2015, 148, 603-615.e14.	1.3	207
3	Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 192-202.	3.7	174
4	Bile Acid Profiling and Quantification in Biofluids Using Ultra-Performance Liquid Chromatography Tandem Mass Spectrometry. <i>Analytical Chemistry</i> , 2015, 87, 9662-9670.	6.5	166
5	MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure. <i>Gut</i> , 2018, 67, 333-347.	12.1	150
6	CD14 ⁺ CD15 ⁺ HLA-DR ⁺ myeloid-derived suppressor cells impair antimicrobial responses in patients with acute-on-chronic liver failure. <i>Gut</i> , 2018, 67, 1155-1167.	12.1	111
7	Mucosa-associated invariant T cells link intestinal immunity with antibacterial immune defects in alcoholic liver disease. <i>Gut</i> , 2018, 67, 918-930.	12.1	106
8	Increased Survival for Patients With Cirrhosis and Organ Failure in Liver Intensive Care and Validation of the Chronic Liver Failure Sequential Organ Failure Scoring System. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1353-1360.e8.	4.4	91
9	Balanced haemostasis with both hypo- and hyper-coagulable features in critically ill patients with acute-on-chronic-liver failure. <i>Journal of Critical Care</i> , 2018, 43, 54-60.	2.2	87
10	Rifaximin ± reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial. <i>Journal of Hepatology</i> , 2022, 76, 332-342.	3.7	79
11	High-Speed Quantitative UPLC-MS Analysis of Multiple Amines in Human Plasma and Serum via Precolumn Derivatization with 6-Aminoquinolyl- <i>N</i> -hydroxysuccinimidyl Carbamate: Application to Acetaminophen-Induced Liver Failure. <i>Analytical Chemistry</i> , 2017, 89, 2478-2487.	6.5	78
12	Multivariate metabotyping of plasma predicts survival in patients with decompensated cirrhosis. <i>Journal of Hepatology</i> , 2016, 64, 1058-1067.	3.7	77
13	Mixed Fibrinolytic Phenotypes in Decompensated Cirrhosis and Acute-on-Chronic Liver Failure with Hypofibrinolysis in Those With Complications and Poor Survival. <i>Hepatology</i> , 2020, 71, 1381-1390.	7.3	63
14	The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin ±. <i>Liver International</i> , 2016, 36, 1295-1303.	3.9	46
15	Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all-cause admissions in patients on the liver transplant waiting list. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 435-441.	3.7	43
16	Global hemostatic status in patients with acute-on-chronic liver failure and sepsis without underlying liver disease. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 85-95.	3.8	38
17	In vitro efficacy of pro- and anticoagulant strategies in compensated and acutely ill patients with cirrhosis. <i>Liver International</i> , 2018, 38, 1988-1996.	3.9	35
18	Immunotherapy in the treatment and prevention of infection in acute-on-chronic liver failure. <i>Immunotherapy</i> , 2015, 7, 641-654.	2.0	32

#	ARTICLE	IF	CITATIONS
19	Dysregulation of the Lysophosphatidylcholine/Autotaxin/Lysophosphatidic Acid Axis in Acute-to-Chronic Liver Failure Is Associated With Mortality and Systemic Inflammation by Lysophosphatidic Acid-Dependent Monocyte Activation. <i>Hepatology</i> , 2021, 74, 907-925.	7.3	28
20	PROFIT, a PROspective, randomised placebo controlled feasibility trial of Faecal microbiota Transplantation in cirrhosis: study protocol for a single-blinded trial. <i>BMJ Open</i> , 2019, 9, e023518.	1.9	27
21	Faecal cytokine profiling as a marker of intestinal inflammation in acutely decompensated cirrhosis. <i>JHEP Reports</i> , 2020, 2, 100151.	4.9	26
22	Neutrophil Toll-Like Receptor 9 Expression and the Systemic Inflammatory Response in Acetaminophen-Induced Acute Liver Failure. <i>Critical Care Medicine</i> , 2016, 44, 43-53.	0.9	24
23	Clinical science workshop: targeting the gut-liver-brain axis. <i>Metabolic Brain Disease</i> , 2016, 31, 1327-1337.	2.9	23
24	Whole blood thrombin generation profiles of patients with cirrhosis explored with a near patient assay. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 834-843.	3.8	22
25	Plasma levels of circulating DNA are associated with outcome, but not with activation of coagulation in decompensated cirrhosis and ACLF. <i>JHEP Reports</i> , 2019, 1, 179-187.	4.9	21
26	Aberrant hepatic trafficking of gut-derived T cells is not specific to primary sclerosing cholangitis. <i>Hepatology</i> , 2022, 75, 518-530.	7.3	21
27	Antimicrobial resistance in chronic liver disease. <i>Hepatology International</i> , 2020, 14, 24-34.	4.2	20
28	Platelet-leucocyte aggregation is augmented in cirrhosis and further increased by platelet transfusion. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1375-1386.	3.7	17
29	Prevalence of Bleeding and Thrombosis in Critically Ill Patients with Chronic Liver Disease. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1006-1016.	3.4	16
30	Therapeutic plasma exchange as a novel treatment for severe intrahepatic cholestasis of pregnancy: Case series and mechanism of action. <i>Journal of Clinical Apheresis</i> , 2018, 33, 638-644.	1.3	12
31	Salivary microbiota-immune profiling in cirrhosis: Could this be the noninvasive strategy that will revolutionize prognostication in hepatology?. <i>Hepatology</i> , 2015, 62, 1001-1003.	7.3	11
32	Fibrin clot quality in acutely ill cirrhosis patients: Relation with outcome and improvement with coagulation factor concentrates. <i>Liver International</i> , 2022, 42, 435-443.	3.9	8
33	Modulating the gut-liver axis and the pivotal role of the faecal microbiome in cirrhosis. <i>Clinical Medicine</i> , 2020, 20, 493-500.	1.9	6
34	Diabetes and the gastrointestinal tract. <i>Medicine</i> , 2011, 39, 288-292.	0.4	4
35	Using a theory-informed approach to explore patient and staff perspectives on factors that influence clinical trial recruitment for patients with cirrhosis and small oesophageal varices. <i>PLoS ONE</i> , 2022, 17, e0263288.	2.5	4
36	OC-029...Rifaximin Is Efficacious In The Treatment Of Chronic Overt Hepatic Encephalopathy: A Uk Liver Multi-centre Experience. <i>Gut</i> , 2014, 63, A14.2-A15.	12.1	3

#	ARTICLE	IF	CITATIONS
37	PTH-106â€¦Plasma S100A8/A9: a novel mechanistic biomarker in innate immune activation in acute-on-chronic liver failure. , 2018, , .		2
38	P: 12â€¦PROFIT: PROspective, Randomised Placebo-controlled Feasibility Trial of Faecal Microbiota Transplantation in Cirrhosis Interim Analysis. American Journal of Gastroenterology, 2019, 114, S5-S7.	0.4	2
39	Images of the month 1: Histoacryl glue embolisation to the right ventricle following treatment for gastric varices. Clinical Medicine, 2022, 22, 163-164.	1.9	2
40	P1119 : Elevated levels of circulating bacterial DNA in alcoholic hepatitis identifies patients who will not respond to corticosteroid. Journal of Hepatology, 2015, 62, S770.	3.7	1
41	Mer Tyrosine Kinase Regulates the Activation of Myeloid Cells and Innate Immune Responses in Acute-on-Chronic Liver Failure. Journal of Hepatology, 2016, 64, S143.	3.7	1
42	PS-174-Serum bile acid profiles distinguish severe alcoholic hepatitis from decompensated alcohol-related cirrhosis. Journal of Hepatology, 2019, 70, e108.	3.7	1
43	THU-052-Immunometabolic profiling of ascites from patients with acute-on-chronic liver failure reveals increased MerTK+ immunosuppressive myeloid cells and cell death markers with preferential lipid metabolism compared to cirrhosis without organ failure. Journal of Hepatology, 2019, 70, e183.	3.7	1
44	P: 71â€¦Faecal Cytokine Profiling Provides Novel Insights Into Intestinal Barrier Disruption and Bacterial Translocation in Acute Decompensation of Cirrhosis. American Journal of Gastroenterology, 2019, 114, S36-S37.	0.4	1
45	Hemostatic balance in acuteâ€¦chronic liver failure. Journal of Thrombosis and Haemostasis, 2021, 19, 869-870.	3.8	1
46	The Lipopolysaccharide-Sensing Caspase(s)-4/11 Are Activated in Cirrhosis and Are Causally Associated With Progression to Multi-Organ Injury. Frontiers in Cell and Developmental Biology, 2021, 9, 668459.	3.7	1
47	P1294 : Proof-of-principle evaluation of immunomodulatory drugs in promoting phagocytosis capacity in patients with liver failure. Journal of Hepatology, 2015, 62, S324.	3.7	0
48	P0168 : The impact on hospital resource utilisation of Rifaximin-alpha for hepatic encephalopathy in routine clinical practice: Real world data from seven UK liver centres. Journal of Hepatology, 2015, 62, S366.	3.7	0
49	O106 : Therapeutic plasma exchange modulates innate immune activation and improves outcome in patients with acute liver failure. Journal of Hepatology, 2015, 62, S246-S247.	3.7	0
50	P1329 : A placebo controlled single centre double blind randomised trial to investigate the efficacy of rifaximin in improving systemic inflammation and neutrophil malfunction in patients with cirrhosis and chronic hepatic encephalopathy (â€¦RIFSYSâ€¦). Journal of Hepatology, 2015, 62, S854.	3.7	0
51	588 The Impact on Hospital Resource Utilization of Rifaximin-â€¦ for Hepatic Encephalopathy in Routine Clinical Practice: Real World Data From Seven UK Liver Centres. Gastroenterology, 2015, 148, S-988.	1.3	0
52	The Formation of Activated Platelet-Complexed Leukocytes is Augmented in Cirrhosis and Enhanced by Platelet Transfusion. Journal of Hepatology, 2016, 64, S526-S527.	3.7	0
53	Altered Gut Microbial Profile is a Proponent of Bacterial Translocation in Acute-on-Chronic Liver Failure. Journal of Hepatology, 2016, 64, S453-S454.	3.7	0
54	FRI-099-PD-1+ monocytes and macrophages contribute to impaired microbial clearance following acute liver failure. Journal of Hepatology, 2019, 70, e430-e431.	3.7	0

#	ARTICLE	IF	CITATIONS
55	THU-055-Improved stratification of liver failure syndromes using broad-panel bile acid LCMS phenotyping demonstrates novel pathways of dysregulation in tertiary bile acids in acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2019, 70, e184-e185.	3.7	0
56	PS-144-Autotaxin mediates lipid dysregulation in acute-on-chronic liver failure, promoting persistence of systemic inflammation via lysophosphatidic acid-mediated monocyte activation. <i>Journal of Hepatology</i> , 2019, 70, e91-e92.	3.7	0
57	P225â€¦Partial splenic artery embolisation for portal hypertension â€œ a single centre experience. , 2021, , .		0
58	Liver transplantation: patient selection, organ allocation, and outcomes. , 2015, , 201-210.		0